Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-5765 tablets have obtained the drug clinical trial approval letter.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., recently received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration for HRS-5765 tablets. The company will soon carry out clinical trials for the treatment of heart failure. HRS-5765 tablets are a new class 1 drug developed independently by the company. Preclinical data shows that HRS-5765 can significantly improve heart function and pathology. As of now, there are no similar drugs approved for market both domestically and internationally. The total research and development investment in the HRS-5765 tablet project is approximately 13.8 million yuan (unaudited).